JUSH Jushi Holdings Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1909747 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.2%
TTM net income YoY15.7%
TTM EPS YoY15.2%
Revenue 3-yr CAGR-0.2%
Net income 3-yr CAGR—
Margins
Gross margin44.2%
Operating margin2.4%
Net margin-20.0%
FCF margin2.2%
EBITDA margin11.1%
Returns
ROE—
ROA-12.9%
ROIC (approx.)8.6%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets136.3%
Debt / equity—
Current ratio0.79x
Interest coverage0.16x
Cash quality & payout
Operating cash flow / net income-0.34x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $70.47M | $71.30M | $66.43M | $68.34M | $65.68M | $65.05M | $63.85M | $65.86M |
| Cost of revenue | $38.14M | $39.77M | $36.55M | $39.72M | $35.02M | $36.12M | $38.07M | $40.45M |
| Gross profit | $32.33M | $31.53M | $29.88M | $28.61M | $30.66M | $28.92M | $25.77M | $25.41M |
| SG&A expense | $28.75M | $29.31M | — | $24.84M | $28.02M | $28.75M | — | — |
| Operating income | $3.51M | $714,000 | $1.58M | $782,000 | $2.34M | $3.60M | -$1.87M | -$1.84M |
| Interest expense | $10.40M | $10.10M | $10.48M | $10.47M | $10.38M | $10.33M | $10.12M | $9.51M |
| Income tax | $6.78M | -$976,000 | $8.72M | $7.25M | $8.83M | $9.93M | $8.98M | $3.59M |
| Net income | -$12.52M | -$7.33M | -$19.85M | -$15.56M | -$23.69M | -$12.33M | -$17.02M | -$12.47M |
| EBITDA | $7.35M | $5.81M | $9.53M | $7.97M | $6.55M | $8.04M | $6.16M | $6.07M |
| EPS (basic) | -0.06 | -0.04 | -0.10 | — | -0.12 | -0.06 | -0.09 | — |
| EPS (diluted) | -0.06 | -0.04 | -0.10 | — | -0.12 | -0.06 | -0.09 | — |
| Weighted avg. shares (diluted) | 198.20M | 198.20M | 198.16M | — | 195.20M | 195.20M | 195.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $28.73M | $33.33M | $39.70M | $24.05M | $26.16M | $25.23M | $27.89M | $21.35M |
| Receivables | $4.46M | $4.19M | $3.73M | $2.80M | $872,000 | $791,000 | $1.40M | $1.46M |
| Inventory | $35.14M | $34.30M | $35.60M | $34.61M | $36.80M | $34.23M | $34.34M | $36.14M |
| Current assets | $74.13M | $77.17M | $84.68M | $68.31M | $68.60M | $64.23M | $68.65M | $72.15M |
| PP&E, net | $136.15M | $137.18M | $141.28M | $143.32M | $144.46M | $144.73M | $143.39M | $144.06M |
| Goodwill | $30.91M | $30.91M | $30.91M | $30.91M | $30.91M | $30.91M | $30.91M | $30.91M |
| Intangibles | $88.23M | $90.54M | $92.78M | $92.20M | $94.80M | $97.02M | $98.91M | $100.47M |
| Total assets | $424.94M | $429.80M | $435.13M | $422.34M | $431.70M | $432.37M | $433.62M | $440.32M |
| Current liabilities | $93.59M | $93.17M | $75.08M | $66.19M | $109.19M | $63.12M | $60.58M | $68.89M |
| Short-term debt | $32.37M | $33.62M | $12.89M | $6.64M | $48.89M | $7.09M | $3.85M | $2.76M |
| Long-term debt | $194.47M | $196.38M | $218.47M | $199.19M | $155.69M | $192.83M | $193.05M | $183.45M |
| Total debt | $226.84M | $230.00M | $231.35M | $205.83M | $204.58M | $199.91M | $196.90M | $186.21M |
| Total liabilities | $578.98M | $571.61M | $569.93M | $537.69M | $533.17M | $510.21M | $499.50M | $490.56M |
| Shareholders' equity | -$154.04M | -$141.82M | -$134.80M | -$115.34M | -$101.47M | -$78.14M | -$66.18M | -$50.23M |
| Net debt | $198.10M | $196.67M | $191.65M | $181.79M | $178.42M | $174.68M | $169.01M | $164.86M |
| Shares outstanding | 199.71M | — | — | — | — | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | $3.54M | $793,000 | $8.61M | $6.05M | $6.08M | -$1.94M | $7.53M | $7.15M |
| Capital expenditure | $2.90M | $3.89M | $3.03M | $3.09M | $4.87M | $4.12M | $4.02M | $2.17M |
| Free cash flow | $637,000 | -$3.10M | $5.58M | $2.96M | $1.21M | -$6.05M | $3.51M | $4.98M |
| Investing cash flow | -$2.93M | -$3.90M | -$4.08M | -$3.07M | -$5.32M | -$459,000 | -$4.38M | -$7.26M |
| Financing cash flow | -$5.20M | -$3.71M | $11.12M | -$2.52M | $166,000 | -$262,000 | $3.39M | -$1.44M |
| Depreciation & amortization | $3.84M | $5.10M | $7.95M | $7.19M | $4.21M | $4.43M | $8.04M | $7.91M |
| Stock-based compensation | $287,000 | $312,000 | $392,000 | $1.68M | $357,000 | $374,000 | -$307,000 | $1.27M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.